These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15252828)

  • 21. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
    Lin KM; Tsou HH; Tsai IJ; Hsiao MC; Hsiao CF; Liu CY; Shen WW; Tang HS; Fang CK; Wu CS; Lu SC; Kuo HW; Liu SC; Chan HW; Hsu YT; Tian JN; Liu YL
    Pharmacogenomics; 2010 Nov; 11(11):1535-43. PubMed ID: 21121774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
    Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
    Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine--a case report.
    Amiaz R; Stein O; Dannon PN; Grunhaus L; Schreiber S
    Psychopharmacology (Berl); 1999 Apr; 143(4):433-4. PubMed ID: 10367562
    [No Abstract]   [Full Text] [Related]  

  • 25. Toxic epidermal necrolysis after paroxetine treatment.
    Ahmed R; Eagleton C
    N Z Med J; 2008 May; 121(1274):86-9. PubMed ID: 18535650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delusional infestation: neural correlates and antipsychotic therapy investigated by multimodal neuroimaging.
    Freudenmann RW; Kölle M; Huwe A; Luster M; Reske SN; Huber M; Lepping P; Wolf RC; Schönfeldt-Lecuona C
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1215-22. PubMed ID: 20600460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
    Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
    J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate].
    Vergouwen AC; Bakker A
    Ned Tijdschr Geneeskd; 2002 Apr; 146(17):811-2. PubMed ID: 12014241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Folie à deux in schizophrenia--"psychogenesis" revisited].
    Shimizu M
    Seishin Shinkeigaku Zasshi; 2004; 106(5):546-63. PubMed ID: 15230353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder.
    Schruers K; Griez E
    J Psychopharmacol; 2004 Dec; 18(4):553-8. PubMed ID: 15582922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
    Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E
    BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
    König F; von Hippel C; Petersdorff T; Neuhöffer-Weiss M; Wolfersdorf M; Kaschka WP
    Neuropsychobiology; 2001; 43(3):170-4. PubMed ID: 11287796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxetine/bupropion combination treatment for refractory depression.
    Marshall RD; Liebowitz MR
    J Clin Psychopharmacol; 1996 Feb; 16(1):80-1. PubMed ID: 8834426
    [No Abstract]   [Full Text] [Related]  

  • 36. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
    Stein DJ; Andersen EW; Tonnoir B; Fineberg N
    Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delusion of Cotard's syndrome successfully treated with a dopamine agonist.
    Takahashi T; Nibuya M; Nomura S
    J Neuropsychiatry Clin Neurosci; 2010; 22(2):E27. PubMed ID: 20463138
    [No Abstract]   [Full Text] [Related]  

  • 38. Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder.
    Heiden A; de Zwaan M; Frey R; Presslich O; Kasper S
    J Psychiatry Neurosci; 1998 May; 23(3):179-80. PubMed ID: 9595892
    [No Abstract]   [Full Text] [Related]  

  • 39. Paroxetine and Study 329: what we already knew and when.
    Sasich LD
    BMJ; 2015 Oct; 351():h5411. PubMed ID: 26468042
    [No Abstract]   [Full Text] [Related]  

  • 40. Paroxetine efficacy in stuttering treatment.
    Boldrini M; Rossi M; Placidi GF
    Int J Neuropsychopharmacol; 2003 Sep; 6(3):311-2. PubMed ID: 12975000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.